To Evaluate the Treatment Effect of an Anti-Infective Agent for Different Kinds of Infections (0826-052)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
20 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Male or female patients, 20 years of age or older
Patients did not receive any systemic antibiotic before enrollment, or patients with failed clinical response (no improvement on symptoms or laboratory data) through previous antibiotic treatment
Patients who required therapy prior to identification of cause of infection
Patient has a concomitant infection that may interfere with the evaluation of the response to ertapenem
Patient has an apache ii > 30.
Patient has an infection caused by pathogens resistant to ertapenem
Patients with known allergy to ertapenem or other drugs in the same carbapenem class, beta - lactams, lidocaine or local anesthetics of the amide type
The patient requires antibiotics other than ertapenem (such as: glycopeptides, macrolides or antifungal agents)